STOCK TITAN

Ovid Therapeutics (OVID) Stock News, Nov 2024-Jun 2025

OVID NASDAQ

Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.

Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.

Rhea-AI Summary

Ovid Therapeutics (NASDAQ:OVID) has entered into a definitive agreement with Immedica Pharma AB to sell its future ganaxolone royalty rights outside China for $7 million in cash. The deal includes the transfer of royalty rights from Ovid's 2022 agreement with Marinus Pharmaceuticals for ganaxolone use in CDKL5 deficiency disorder (CDD). Immedica will also acquire or license Ovid's global ganaxolone intellectual property portfolio and assume related costs.

The transaction provides non-dilutive funding to extend Ovid's operational runway. For reference, Ovid recorded $566,000 in ganaxolone royalty revenues in 2024. The deal has no impact on Ovid's current pipeline as the company has not been pursuing ganaxolone development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
Rhea-AI Summary
Ovid Therapeutics (NASDAQ: OVID) will host an investor and media event on June 12, 2025, focusing on biomarkers in epilepsy and their OV329 clinical development program. The event will feature Dr. Alexander Rotenberg, a leading pediatric neurologist from Boston Children's Hospital and Harvard Medical School. The presentation will highlight how advanced imaging and radiological tools are being used to identify biological target engagement in drug development. OV329, Ovid's next-generation GABA-aminotransferase inhibitor, is designed to address treatment-resistant seizures, with topline results expected in Q3 2025. The drug aims to provide optimal GABA levels with better safety and tolerability compared to vigabatrin. Currently, about 40% of epilepsy patients continue experiencing seizures despite available treatments. The event will be held at Ovid's New York headquarters and simultaneously webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.20%
Tags
conferences
-
Rhea-AI Summary
Ovid Therapeutics (NASDAQ: OVID) reported Q1 2025 financial results and pipeline updates. The company's lead program OV329, a GABA-AT inhibitor for drug-resistant epilepsies, is progressing with topline results expected in Q3 2025. Their OV350 program, the first-ever KCC2 direct activator, began Phase 1 trials in Q1 2025. The company reported $43.0 million in cash and equivalents, expected to fund operations into 2H 2026. Q1 financial results showed revenues of $130,000, R&D expenses of $6.7 million (down from $10.4M), and a net loss of $10.2 million ($0.14 per share). The company's pipeline includes multiple promising candidates, with their oral KCC2 activator OV4071 planned for clinical development by year-end, targeting psychosis in neuronal-synuclein diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.30%
Tags
Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's President and Chief Operating Officer, Meg Alexander, will deliver a presentation on Monday, April 7, 2025, at 8:45 AM ET.

Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
conferences
-
Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID) reported its Q4 and full-year 2024 financial results, highlighting key pipeline developments and organizational updates. The company ended 2024 with $53.1 million in cash and equivalents, expected to fund operations into H2 2026.

Key developments include: appointment of Dr. Stelios Papadopolous to the Board of Directors; anticipated topline results from OV329's Phase 1 study in Q3 2025; and initiation of first-in-human study for OV350 in Q1 2025. The company reported full-year 2024 revenues of $566,000 and a net loss of $26.4 million ($0.37 per share).

Pipeline updates include:

  • OV329: Phase 1 study progressing with no serious adverse events reported
  • OV350: First KCC2 direct activator initiated human trials
  • OV4071: First oral KCC2 activator targeting human studies in Q2 2026
  • OV888/GV101: Phase 2 proof-of-concept study paused for strategic evaluation

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) has appointed Dr. Stelios Papadopoulos to its Board of Directors. Dr. Papadopoulos, a renowned scientist, investor, and entrepreneur with over four decades of biotechnology experience, will serve on the company's Audit and Compensation Committees.

The appointment comes at a strategic time as Ovid advances its pipeline, including novel KCC2 direct activators and OV329 epilepsy program, focusing on developing small-molecule medicines for brain conditions with significant unmet need.

Dr. Papadopoulos brings extensive experience from his roles at Cowen & Co., PaineWebber, and academic positions. He currently serves as Chairman of Exelixis and Regulus Therapeutics, and was previously Chairman of Biogen. He holds an MS in physics, PhD in biophysics, and MBA in finance from New York University.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
management
Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Meg Alexander, President and Chief Operating Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.

Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a virtual presentation on Wednesday, February 12, 2025, at 4:00 p.m. ET.

Interested parties can access the live webcast through the Events & Presentations section on the company's investor website at investors.ovidrx.com. For those unable to attend the live session, an archived replay will be made available on the company's website after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
conferences
-
Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) announced the presentation of four posters at the 2024 American Epilepsy Society Annual Meeting in Los Angeles, highlighting their pipeline programs targeting neuronal hyperexcitability. The presentations focus on two key compounds: OV329, a next-generation GABA aminotransferase inhibitor, and OV350, a KCC2 direct activator.

The research demonstrates OV329's improved safety profile and lack of ocular accumulation compared to vigabatrin, along with its effectiveness in elevating GABA and suppressing seizures. Studies also show OV350's potential in treating nerve agent-induced benzodiazepine-resistant refractory status epilepticus. The company aims to be the first to study a KCC2 direct activator in humans next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences
Rhea-AI Summary

Ovid Therapeutics reported Q3 2024 financial results and business updates. The company's Phase 1 SAD/MAD study of OV329 is progressing with plans to expand dosing opportunities. A regulatory application for OV350 Phase 1 trial is expected in Q4 2024. The company has paused Phase 2 study of OV888/GV101 to evaluate competitor trial insights. Financial position shows $62.7 million in cash and marketable securities, expected to support operations into H2 2026. Q3 results include revenue of $173,000, R&D expenses of $7.9 million, and a net loss of $14.0 million ($0.20 per share).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags

FAQ

What is the current stock price of Ovid Therapeutics (OVID)?

Ovid Therapeutics (OVID) last closed at $2.22.

What is the market cap of Ovid Therapeutics (OVID)?

The market cap of Ovid Therapeutics (OVID) is approximately $419.0M.